Ilya Goldshleger sold $170k of RXST
See remarks at RxSight, Inc.. 3,100 shares at an average of $55.00, traded Nov 7, 2024, filed Nov 8, 2024.
Score components
- +15RoleOfficer
- +11Trade size$170k at market
- 0Share of holdings soldSold 6.8% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.1%, 3m -31.2%, 6m -72.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-124035, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2024 | MOption exercise Common Stock10b5-1 | +3,100 | $15.08 | $47k | 45,346 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stock10b5-1 | -2,900 | $54.96 | $159k | 42,446 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stock10b5-1 | -200 | $55.53 | $11k | 42,246 | Nov 8, 2024 |
| Nov 7, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,100 | $0.00 | $0 | 59,387 | Nov 8, 2024 |
Related signals
Other insiders at RxSight, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | RxSight, Inc. | Ilya Goldshleger Chief Operating Officer | $14k 2,041 shares | -2% | |
| 21Weak | RxSight, Inc. | Ronald M Kurtz MD Chief Medical Officer | $35k 5,100 shares | -7% | |
| 15Weak | RxSight, Inc. | Eric Weinberg See remarks | $14k 2,041 shares | -1% | |
| 34Weak | RxSight, Inc. | Mark Wilterding Chief Financial Officer | $54k 7,765 shares | -24% | |
| 12Weak | RxSight, Inc. | Tamara Fountain director | $180k 7,000 shares | -22% | |
| 38Weak | RXSTbuy RxSight, Inc. | Jesse Anderson Corley director | $100k 3,210 shares | - | |
| 0Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $143k 3,105 shares | -7% | |
| 7Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $282k 6,200 shares | -14% | |
| 24Weak | RxSight, Inc. | Shweta Maniar director | $174k 3,782 shares | -26% | |
| 8Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $364k 7,975 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.